All In Biotech

Drug Trial Radar · NCT00000655

A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients

A Randomized, Double-Blind Study of 566C80 Versus Septra (Trimethoprim/Sulfamethoxazole) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients

Last checked: Nov 20, 2026Latest source record: Mar 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

300

Actual

Start

Not stated

Primary completion

Jan 1992

Sponsor

Sponsor type
NIH
Collaborators
Glaxo Wellcome
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients. To compare the safety of short-term (21 days) treatment with 566C80 and SMX/TMP in AIDS patients with an acute episode of PCP. Standard therapies for acute treatment of PCP involve either SMX/TMP or pentamidine isetionate. Although both treatments are equally effective, side effects prevent completion of therapy in 11-55 percent of patients.

Conditions

  • Pneumonia, Pneumocystis Carinii
  • HIV Infections

Interventions

  • AtovaquoneDrug

  • Sulfamethoxazole-TrimethoprimDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

38 sites in 8 countries. Site status is shown where the registry gives one.

  • Univ of Alabama at Birmingham

    Birmingham, Alabama

  • Kaiser Foundation Hosp

    Harbor City, California

  • USC

    Los Angeles, California

  • Dr Richard Meyer

    Los Angeles, California

  • UCLA CARE Ctr

    Los Angeles, California

  • Infectious Disease Med Group

    Oakland, California

  • Univ of California / San Diego Treatment Ctr

    San Diego, California

  • San Francisco Gen Hosp

    San Francisco, California

  • UCSF - San Francisco Gen Hosp

    San Francisco, California

  • Dr Marcus Conant

    San Francisco, California

  • Georgetown Univ Med Ctr

    Washington D.C., District of Columbia

  • Veterans Administration Med Ctr

    Washington D.C., District of Columbia

  • Dr Winkler Weinberg

    Roswell, Georgia

  • Johns Hopkins Univ School of Medicine

    Baltimore, Maryland

  • Natl Inst of Allergy & Infect Dis / Cln Ctr

    Bethesda, Maryland

  • Washington Univ School of Medicine

    St Louis, Missouri

  • Beth Israel Med Ctr / Peter Krueger Clinic

    New York, New York

  • Saint Vincent's Hosp and Med Ctr

    New York, New York

  • Harlem AIDS Treatment Group / Harlem Hosp Ctr

    New York, New York

  • Duke Univ Med Ctr

    Durham, North Carolina

  • Univ of Cincinnati

    Cincinnati, Ohio

  • Good Samaritan Hosp

    Portland, Oregon

  • Buckley Braffman Stern Med Associates

    Philadelphia, Pennsylvania

  • Regional Med Ctr at Memphis

    Memphis, Tennessee

  • The Regional Medical Ctr, Memphis

    Memphis, Tennessee

  • Plaza Med Ctr

    Houston, Texas

  • Baylor College of Medicine

    Houston, Texas

  • CHU Saint Pierre

    Brussels, Belgium

  • Dr Julio S G Montaner

    Vancouver, British Columbia, Canada

  • Wellesley Hosp

    Toronto, Ontario, Canada

  • Montreal Gen Hosp

    Montreal, Quebec, Canada

  • Hopital Bichat - Claude Bernard

    Paris, France

  • August-Viktoria-Krankenhaus Chefarst derII Inneren Abteilung

    Berlin, Germany

  • Universitat Munchen / Medizinische Poliklinik

    Munich, Germany

  • Natac Med Centre

    Amsterdam, Netherlands

  • San Juan Veterans Administration Med Ctr

    San Juan, Puerto Rico

  • Kobler Centre / Saint Stephen's Hosp

    London, United Kingdom

  • Saint Mary's Hosp

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.